
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including Diffuse Large B-Cell Lymphoma

Graham P. Collins¹, William Townsend², Ahmed Abdulgawad³, Swathi Namburi⁴, Anja Williams⁵, Ana Filipa Palma Dos Reis⁶, Matthew G. Krebs⁷, Jeff Evans⁸, Sarah P. Blagden⁹, Ruth Plummer¹⁰, Daniel Hochhauser², Adam Sharp¹¹, George Cole¹², Seema Rogers¹², Daniel Chan¹², Sarah Whelan¹², Dima El-Sharkawi¹³ ⁷The Christie NHS Foundation Trust, University of Manchester, UK; ¹⁰Northern Centre for Care, Newcastle upon Tyne, UK; ¹¹The Institute of Cancer Research, and the Royal Marsden Hospital, London, UK; ¹²Nurix Therapeutics, Inc., San Francisco, CA, USA; ¹³Royal Marsden NHS Foundation Trust, Sutton, UK

Background

- Effective treatment for recurrent DLBCL is a high unmet medical need despite the advances of novel modalities such as cell- and immune-mediated therapies.
- T-cell dysfunction and emerging resistance to T-cell-mediated therapies such as CAR-T and T-cell engagers suggest a potential role for novel therapies that can both enhance T-cell function to overcome a suppressive TME and prevent tumor escape associated with low tumor antigen expression
- CBL-B is an E3 ubiquitin ligase expressed in immune cells that regulates T-cell activation. CBL-B inhibition reduces T-cell exhaustion and increases cytokine production upon TCR stimulation, overcoming suppressive TME signals.^{1–3} Furthermore, lack of CBL-B allows T-cell activation despite low target antigen expression on tumor cells,⁴ potentially reversing the tumor escape mechanism of resistance.
- NX-1607 is an oral small-molecule inhibitor of CBL-B that enhances innate and adaptive immune responses (Figure 1):
- NX-1607 has demonstrated anti-tumor activity and long-term survival in murine models as a single agent and in combination with PD-1 antibodies.^{2,5}
- Furthermore, NX-1607 elicits dose-dependent increases in cytokine secretion and proliferation in TCR-stimulated primary human T cells with enhanced tumor antigen-specific T-cell and NKcell anti-tumor responses.^{2,5}
- NX-1607 may, as a single agent, enhance the efficacy of endogenous T-cell- and NK-cellmediated anti-tumor activity, thus supplementing and rescuing CAR-T or NK cell therapies in patients with hematologic malignancies that have developed resistance.


Figure 1. NX-1607: Proposed mechanism of action



Methods

NX-1607-101 is a first-in-human, multicenter, open-label, Phase 1a/1b dose-escalation/expansion trial evaluating the safety, tolerability, PK/PD, and preliminary anti-tumor activity of NX-1607 in patients with advanced malignancies, including DLBCL (Figure 2).

Figure 2. Study design (ClinicalTrials.gov NCT05107674)



^aStarting dose for NX-1607 in Arm 2 will be ≥1 dose level below the highest previously cleared monotherapy dose level and dosing regimen. ^bCombination indications for Arm 2 may include platinum-resistant EOC, gastric cancer, HNSCC, NSCLC, TNBC, urothelial cancer, cervical cancer. ^cIncluding primary peritoneal and fallopian tube carcinoma. ^dIncludes metastatic or unresectable disease. ^eIncludes MPM, TNBC, locally advanced/metastatic urothelial cancer, cervical cancer, MSS CRC- or DLBCL/DLBCL-RT.

Phase 1a accelerated and 3+3 dose-escalation design

Arm 1 NX-1607 monotherapy

- Modified Fibonacci dose-escalation design of 1 patient per NX-1607 dose level until first observation of grade ≥2 AE starting with Dose Level 1 (5 mg QD).
- Following occurrence of grade ≥2 AE during Cycle 1 with no clear alternative explanation for causality, escalation will change to a 3+3 dose escalation.

Phase 1a dose-escalation **Primary Objectives** Safety and tolerability MTD and/or RP1bD **Secondary Objectives** • PK/PD of NX-1607 Preliminary anti-tumor activity Tumor markers of response Possible Phase 1b dose-expansion **Primary Objective:** Antitumor activity at the RP1bD(s)

Secondary Objectives

- Safety and tolerability
- Preliminary anti-tumor activity
- PK/PD of NX-1607

Exploratory Objectives

- Biomarkers of CBL-B inhibition and mechanisms of response/resistance:
- Changes in immune profiles in circulation post-exposure
- Characterizing systemic immune signatures
- Gene expression & mutation analysis
- NX-1607 metabolites

Patient cohorts and inclusion criteria

General	Indication-specific	
Inclusion criteria • Age ≥18 years	HNSCC Previously received a PD-1 or PD-L1 inhibitor in advanced setting if eligible 	MPM • ≥1 prior therapy including platinum-based chemotherapy or CPI
 Measurable metastatic or unresectable disease Received or not candidates for standard treatment options ECOG performance status 0 or 1 	 EOC Platinum-resistant but documented disease progression within 6 months Platinum-refractory provided refractory in second line or later 	 Urothelial cancer Previously received a PD-1 or PD-L1 inhibitor and/or platinum chemotherapy CA-125 ≥2 x ULN
 Phase 1b only: accessible tumor or lymph node (DLBCL only) for biopsy 	 DLBCL/DLBCL-RT DLBCL-RT: ≥ 1 lines standard therapy; must have responded to treatment 	 MSS CRC ≥2 prior lines including irinotecan, fluoropyrimidine, and/or oxaliplatin Prior EGFR inhibitor if known <i>Ras</i> wild type
Exclusion criteria Active untreated brain metastases Treatment with CPI within 3 weeks	 Non-RT DLBCL: ≥2 lines standard therapy ≥1 measurable site and ≥ 2 lesions^a No progressive multifocal leukoencephalopathy 	
 Prior radiotherapy within 2 weeks CAR-T therapy within 30 days Stem cell transplant within 100 days History of uveitis 	 mCRPC ≥2 prior lines in advanced setting including androgen receptor- directed therapy and taxane-based chemotherapy Radiographic progression by bone scan 	Melanoma Prior CPI if tumors express PD-L1 Prior BRAF inhibitor if tumor is <i>BRAF</i> mutation positive
 Inability to swallow capsules Major surgery planned within 4 weeks 	Cervical cancer • ≥1 prior lines including platinum-based chemotherapy • Prior CPI if tumor expresses PD-L1	TNBC • ≥2 prior lines for metastatic disease • Including PARP inhibitor for gBRCAm, HER2-TNBC
Denotes hematology-oncology indication ^a Clearly demarcated lesions/nodes with long axis >1.5 cm and short axis >1.0 cm or 1 clearly	NSCLC Prior therapy as applicable including anti-PD-1 or PD-L1 	Gastric or GEJ adenocarcinoma ≥2 prior lines including platinum- and fluoropyrimidine-containing chemotherapy and HER2-targeted therapy if appropriate

demarcated lesion/node with a long axis >2.0 cm and short axis ≥1.0 cm AND baseline FDG PET scans must demonstrate positive lesion compatible with CT (or MRI) defined anatomical tumor sites

Primary Endpoints • TEAEs, including grade \geq 3 TEAEs, SAEs, discontinuations, deaths due to TEAEs, irAEs Deaths • DLTs Secondary Endpoints • NX-1607 PK parameters in plasma Changes in biomarkers in circulating immune cells • ORR

Primary Endpoint: ORR

Secondary Endpoints

- TEAEs; irAEs; deaths
- Changes from baseline in safety parameters
- DOR, DCR, PFS, OS, TTP
- NX-1607 PK parameters in plasma
- Changes in biomarkers in the blood and within tumor tissue
- Changes in tumor tissue biopsies of immune cell infiltration or other
- histological features

Phase 1a/1b exploratory

Exploratory Endpoints

- CBL-B signaling pathway analysis:
- Changes in biomarkers in the blood and within tumor tissue
- Changes in circulating blood tumor-specific biomarkers (e.g., CEA)

Indication_enocific

Sample size and statistics


- Up to 303 patients will be enrolled at approximately 20 sites in the United States and United Kingdom and treated until disease progression or unacceptable toxicity.
- Phase 1a dose escalation:
- Up to 109 evaluable patients in monotherapy dose-escalation stage, dependent on number of dose levels investigated.
- Phase 1b dose expansion:
- Up to 194 patients in the monotherapy dose-expansion phase.

Biomarker analyses

- Biomarkers of CBL-B signaling pathway and target engagement may include: Evaluation of immune cell infiltration into tumor.
- Assessment of immune profiles in circulation following exposure.
- Characterization of systemic immune signatures.
- Analysis of gene expression & mutational landscape.

Current status

• Dose escalation is ongoing at 14 locations in the United States and United Kingdom.



References

- 1. Gosling J, et al. Cancer Res 2019;79(13Suppl):2696.
- 2. Rountree R, et al. Cancer Res 2021;81(13Suppl):1595.
- 3. Galotta M, et al. J Immunother Cancer 2022;10(Suppl 2):A348.
- 4. Stromnes IM. et al. J Clin Invest 2010:120:3722-34.
- 5. Nurix Therapeutics. Inhibitors of the E3 ubiquitin ligase CBL-B promote potent T and NK cell mediated anti-tumor response. 17th Annual Drug Discovery Chemistry, Apr 19, 2022. San Diego, CA, USA.
- 6. Fourie Zirkelbach J, et al. J Clin Oncol 2022;40:3489–500.

Abbreviations

AE, adverse event; BID, twice daily; CAR-T, chimeric antigen receptor T-cell; CBL-B, Casitas B-lineage lymphoma B; CD, cluster of differentiation; CPI, checkpoint inhibitor; DCR, disease control rate; DLBCL, diffuse large B-cell lymphoma; DLBCL-RT, diffuse large B-cell lymphoma with Richter transformation; DLT, dose-limiting toxicity; **DOR**, duration of response; **ECOG**, Eastern Cooperative Oncology Group; **EOC**, epithelial ovarian cancer; HNSCC, head and neck squamous cell carcinoma; IL-2, interleukin-2; irAE, immune-related adverse event; mCRPC, metastatic castrate-resistant prostate cancer; MHC, major histocompatibility complex; **MPM**, malignant pleural mesothelioma; **MSS CRC**, microsatellite stable colorectal cancer; MTD, maximum tolerated dose; NSCLC, non-small-cell lung cancer; ORR, objective response rate; **OS**, overall survival; **PD**, pharmacodynamics; **PD-1**, programmed cell death protein-1; **PK**, pharmacokinetics; QD, once daily; RP1bD, recommended Phase 1b dose; TCR, T-cell receptor; TEAE, treatment-emergent adverse event; **TME**, tumor microenvironment; TNBC, triple-negative breast cancer

Acknowledgments

• NX-1607-101 was sponsored by Nurix Therapeutics, Inc. Nurix Therapeutics, Inc. also funded the editorial/layout support for this poster, which was provided by Miller Medical Communications. Clinical trial information: NCT05107674. Study contact: nx1607101@nurixtx.com



For information about this clinical trial please follow the QR code